Sabrina Apitz-Grossman, a 31-year-old diagnosed with a rare form of cancer that spread to her lungs, was given a limited time to live. Despite undergoing various treatments, the synovial sarcoma remains a significant challenge.
Facing a crucial need for a specialized treatment unavailable in Ontario, Apitz-Grossman encountered obstacles in accessing out-of-country coverage from the Ontario Health Insurance Plan. Her plea for the treatment to be administered at a local cancer center was also denied through an appeal.
In a recent turn of events, the rules governing out-of-country drug coverage have been tightened, drawing criticism from patients in similar situations. Health Minister Sylvia Jones defended the policy change, emphasizing cost-saving measures and the importance of maintaining Ontario’s drug approval process.
Apitz-Grossman’s desired treatment, Tecelra, offers promising results but comes at a high cost. Despite feeling conflicted about the expenses, she is determined to fight for her chance at survival.
